Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 14/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21629662 | 0.84 | GRM4 (0.57) | GRM4KDRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL14183004 | 0.84 | GRM4 (0.53) | GRM4KDRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL21677294 | 0.83 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2ITK | |
| SCHEMBL21629670 | 0.81 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2ITK | |
| SCHEMBL21629657 | 0.80 | ITK (0.41) | KDRNPC1RAB9AITK | |
| SCHEMBL21677355 | 0.79 | ITK (0.59) | NPC1RAB9ASMN1; SMN2KDM4EITK | |
| SCHEMBL21677248 | 0.79 | ITK (0.42) | KDRNPC1RAB9AITK | |
| SCHEMBL20482953 | 0.78 | GRM1 (0.49) | NPC1RAB9ASMN1; SMN2HDAC6ITK | |
| SCHEMBL14182794 | 0.77 | KDR (0.46) | GRM4KDRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8297618 | 0.76 | NPC1 (0.59) | GRM4KDRNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031805-A1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATOR COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031805-A1 | ARYL HYDROCARBON RECEPTOR (AHR) MODULATOR COMPOUNDS | AHR, ARNT, AIPL1 | GRM4 1436/4885KDR 1139/4885NPC1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.